This strong CAR T cell expansion came to an end after day 13, aligning with a plateau of the anti-tumor effect in EGFR CAR T cell treated animals between day 16 and day 20, indicating an end of the active tumor-killing phase. The gene discussed is EGFR; the disease is neoplasm.